ArticleBMC infectious diseases2020
Mycoplasma pneumoniae pneumonia associated thrombosis at Beijing Children's hospital.
Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Pentasystem embolism associated with transient antiphospholipid antibodies in severe M.Frontiers in immunology · 2026Pooled it
- Analysis of the Nursing Effect of Respiratory Critical Illness Based on Refined Nursing Management.Computational and mathematical methods in medicine · 2022Trial
- Mycoplasma pneumoniae infections in the Post-COVID era: recent advances from pathogenesis to clinical management.Infection · 2026Review
- Risk factors for plastic bronchitis complicating severeTranslational pediatrics · 2026Article
- Neutrophils promote endothelial cell activation in pediatric Mycoplasma pneumoniae pneumonia.JCI insight · 2026Article
- Advances in treatment and prevention of pulmonary thromboembolism associated with Mycoplasma pneumoniae pneumonia in children.Pediatric research · 2026Review
- Independent risk factors for refractory mycoplasma pneumoniae pneumonia in children: a multivariate analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- East Asia as a sentinel: risk-stratified corticosteroid therapy for paediatric macrolide-resistantEuropean respiratory review : an official journal of the European Respiratory Society · 2026Review
- High-Risk CCL14 lineage drives severe Mycoplasma pneumoniae pneumonia in children: a study in central China.Clinical and experimental pediatrics · 2026Article
- Construction of a risk prediction model for multiple bronchoalveolar lavages in children with necrotizing pneumonia based on LASSO regression.Pediatric research · 2026Article
- From Respiratory Pathogen to Systemic Threat: RethinkingMicroorganisms · 2026Review
- Factors associated with pulmonary embolism in children with refractoryFrontiers in pediatrics · 2026Article
- Exploring Clinical Characteristics and Risk Factors ofJournal of inflammation research · 2026Article
- Predictive Performance of a Serum sRAGE/sVEGFR-3 Dual-Biomarker Combination for Hypercoagulability Status in PediatricInternational journal of general medicine · 2026Article
- Mechanical Thrombectomy for Acute Vertebrobasilar Occlusion Associated withJournal of neuroendovascular therapy · 2026Article
- PLR/SII/D-dimer iron triangle: a novel precision prediction strategy forFrontiers in medicine · 2026Article
- A causal forest model integrating quantitative CT scores to predict benefit from flexible bronchoscopy in pediatric Mycoplasma pneumoniae pneumonia: a two-center retrospective study.Respiratory research · 2025Article
- Article
- Quantitative analysis of pulmonary vascular alterations in children with refractoryQuantitative imaging in medicine and surgery · 2025Article
- Surgical treatment intracardiac thrombosis and pulmonary embolism complication of Mycoplasma pneumoniae pneumonia: a case report.Journal of cardiothoracic surgery · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundWith the increase of awareness of mycoplasma pneumoniae pneumonia (MPP), we found thrombosis in severe MPP (SMPP) was not rare. The aim of the study was to investigate the clinical characteristics, treatment, and long-term prognosis of MPP-associated thrombosis.
methodsWe retrospectively reviewed the medical records of 43 children with MPP-associated thrombosis between January 2013 and June 2019 at Beijing Children's Hospital. The results of blood coagulation studies, autoimmune antibody, thrombophilia screening, contrast-enhanced lung computed tomography, echocardiography, and blood vessel ultrasonography were analyzed, as were treatment outcomes.
resultsForty-two patients were diagnosed with SMPP. D-dimer was higher than 5.0 mg/L in 58.1% (25/43) of patients. The mean D-dimer level was 11.1 ± 12.4 mg/L. Anticardiolipin-IgM was positive in 60.0% of patients, β2-glycoprotein-IgM in 64.0%, and lupus anticoagulant in 42.1%. Chest imaging revealed pulmonary consolidation with lobe distribution in all patients (2/3-1 lobe in 10 patients, > 1 lobe in 29 patients). In our experience, thrombosis can occur in a vessel of any part of the body, and it can be initially detected as late as 31 days after disease onset. Thrombosis in the brain and abdomen can occur early, at 5 days after disease onset. Pulmonary vessels were the most commonly involved sites in the current study, and accordingly chest pain was the most common symptom (32.6%), followed by neurological symptoms (14.0%) and abdominal pain (9.3%). Thirty-five percent of patients were asymptomatic with regard to thrombosis. All patients underwent anticoagulant therapy, and thrombus absorption took > 3 months in most patients. All patients were followed until October 2019, at which time 41 were asymptomatic and 2 had mild recurrent cough.
conclusionsSMPP with pulmonary consolidation (> 2/3 lobe) was the most strongly associated risk factor for thrombosis. Thrombosis-associated symptoms may be subtle, even absent. Elevated D-dimer, specifically > 11.1 mg/L (even > 5.0 mg/L), would assist in the early diagnosis of thrombosis. The long-term prognosis of thrombosis was good after timely administration of anticoagulant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.